Cholinesterase inhibitors: New roles and therapeutic alternatives

Pharmacological Research

Volumn 50, Issue 4, 2004, Pages 433-440

  Giacobini, Ezio ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Alzheimer disease; Butyrylcholinesterase; Cholinesterase inhibitors; Delirium; Dementia with Lewy bodies; Down Syndrome; Parkinson dementia; Traumatic brain injury; Vascular dementia

Indexed keywords

1,5 BIS(4 ALLYLDIMETHYLAMMONIUMPHENYL)PENTAN 3 ONE DIBROMIDE; ACETYLCHOLINE; BAMBUTEROL; BISNORCYMSERINE; BRAIN ENZYME; CHOLINESTERASE INHIBITOR; CYMSERINE; DONEPEZIL; GALANTAMINE; HEPTYLSTIGMINE TARTRATE; HETOPROPAZINE; HUPERZINE A; HUPERZINE B; ISO OMPA; LITHIUM; MEMANTINE; METRIFONATE; MF 8622; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE; PHENSERINE; PHENYLETHYLCYMSERINE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE; THIAMINE; UNCLASSIFIED DRUG;

AGITATION; ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ARTICLE; BRAIN; BRAIN INJURY; CHOLINERGIC SYSTEM; CLINICAL TRIAL; DELIRIUM; DEMENTIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN SYNDROME; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYDROLYSIS; INCONTINENCE; KINETICS; MIGRAINE; MULTIINFARCT DEMENTIA; NONHUMAN; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; SIDE EFFECT; THIAMINE DEFICIENCY; VISUAL HALLUCINATION; WERNICKE KORSAKOFF SYNDROME; ZYGOTE;

ACETYLCHOLINESTERASE; BRAIN; BRAIN DISEASES; CHOLINESTERASE INHIBITORS; HUMANS; TREATMENT OUTCOME;

EID: 4043074138     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2003.11.017     Document Type: Article

References (52)

1. Silver A. The biology of cholinesterases. Agricultural Research Council Inst. USA: Elsevier; 1974. p. 426-47.
2. Giacobini E. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drug Aging. 18:2001;891-898
3. Wright C.I., Geula C., Mesulam M.M. Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles and patterns of selective vulnerability. Ann. Neurol. 34:1993;373-384
4. Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl. Neurobiol. 4:1978;273-277
5. Cuadra G., Summers K., Giacobini E. Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. J. Pharmacol Exp. Ther. 270:1994;277-284
6. Giacobini E., Griffini P.L., Maggi T. The effect of MF8622, a selective butyrylcholinesterase inhibitor on cortical levels of acetylcholine. Soc. Neurosci. 22:1996;203
7. Greig N.H., Utsuki T., Yu Q. Butyrylcholinesterase: a new therapeutic target in Ad treatment? Alz. Insights. 7(2):2001;1-4
8. Mesulam M.M., Guillozet A., Shaw P., Levey A., Duysen E.G., Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butylcholinesterase to hydrolyse acetylocholine. Neuroscience. 110:2002;627-639
9. Mesulam M.M., Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann. Neurol. 36:1994;722-727
10. Inestrosa N.C., Alvarez A., Reyes A., De Ferrari G.V. Acetylcholinesterase-amyloid-peptide interaction and Wnt signaling involvment in A-beta neurotoxicity. Acta Neurol. Scand. 176(Suppl):2000;53-59
11. Darvesh S., MacKnight C., Rockwood K. Butyrylcholinesterase and cognitive function. Int. Psychogeriatr. 13:2001;461-464
12. Lahiri DK, Farlow MR, Ge YW, Sambamurti K, Utsuki T, Ingram DK, et al. Phenserine: a new generation of cholinesterase inhibitors with amyloid-modifying properties. in: Proceedings of the 7th International Geneva Springfield Symposium. 2002. p. 80 [abstract].
13. Shaw K., Utsuki T., Rogers J., Qiang-Sheng Y., Sambamurti K., Brossi A. Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc. Natl. Acad. Sci. USA. 19:2001;7605-7610
14. Haroutunian V, Wallace WC, Greig N. Induction, secretion and pharmacological regulation of beta-APP in animal model systems. in: Proceedings of the Sixth International Stockholm/Springfield Symposium Advances in Alzheimer Therapy. 2000. p. 81 [abstract].
15. Costa J, Anand R, Cutler N. Correlation between cognitive effects and level of acetylcholinesterase inhibition in a trial of rivastigmine in Alzheimer's patients. Proc Am Psych Assoc 1999;Poster NR:561.
16. Giacobini E. Acetyl- and butyrylcholinesterase inhibition by rivastigmine in cerebrospinal fluid of patients with Alzheimer's disease correlates with cognitive benefit. J. Neural Trans. 109:2002;1053-1065
17. Fox N.C., Warrington E.K., Seiffer A.L., Agnew S.K., Rossor M.N. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. Brain. 121:1998;1631-1639
18. Sunderland T. Cholinergic therapy. Am. J. Geriatr. Psychiatry. 6(Suppl 1):1998;57-63
19. Stirling Meyer J., Li Y., Xu G., Thornby J., Chowdhury M., Quach M. Feasibility of treating mild cognitive impairment with cholinesterase inhibitors. Int. J. Geriatr. Psychiatry. 17:2002;586-588
20. Perry E.K., McKeith I.G., Perry R.H. Dementia with Lewy bodies: a common cause of dementia with therapeutic potential. Int. J. Geriatr. Pharmacol. 1:1998;120-125
21. McKeith I., Del Ser T., Spano P., Emre M., Wesnes K., Anand R., et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 356:2000;2031-2036
22. Werber E.A., Rabey J.M. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J. Neural. Trans. 108(11):2001;1319-1325
23. Kumar V., Anand R., Messina J., Hartman R., Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur. J. Neurol. 7:2000;159-169
24. Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Damaraju C.V. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 359:2002;1283-1290
25. Pratt RD, Perdomo CA, The Donepezil 307VaD Study Group. Donepezil improves cognition in patients with vascular dementia: results from study 307, a 24-week, randomized, double-blind, placebo-controlled trial. in: Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva, Switzerland, 3-6 April 2002.
26. Moretti R., Torre P., Antonello R.M., Cazzato G. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. Eur. J. Neurol. 8:2001;361-362
27. Kishnani P.S., Sullivan J.A., Walter B.K., Spiridigliozzi G.A., Doraiswamy P.M., Krishnan K.R.R. Cholinergic therapy for Downs' syndrome. Lancet. 353:1999;1064-1065
28. Hemingway-Eltomey J.M., Lerner A.J. Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome. Am. J. Psychiatry. 156(9):1999;1470
29. Kishnani P.S., Spiridigliozzi G.A., Heller J.H., Sullivan J.A., Doraiswamy P.M., Krishnan K.R.R. Donepezil for Down's syndrome. Am. J. Psychiatry. 158:2001;143
30. Prasher V.P., Huxley A., Haque M.S. The Down Syndrome Ageing Study Group A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease - pilot study. Int. J. Geriatr. Psychiatry. 17:2002;270-278
31. Lott I.T., Osann K., Doran E., Nelson L. Down syndrome and Alzheimer disease: response to donepezil. Arch. Neurol. 59(7):2002;1133-1136
32. Chen Y., Shohami E., Bass R., Weinstock M. Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat. Brain Res. 784:1998;18-24
33. Goldberg E., Gerstman L.J., Mattis S., Hugues J.E.O., Sirio C.A., Bilder R.M. Jr. Selective effects of cholinergic treatment on verbal memory in posttraumatic amnesia. J. Clin. Neuropsychol. 4:1982;219-234
34. Levin H.S., Peters B.H., Kalisky Z., High W.H. Jr., von Laufen A., Eisenberg H.M. Effects of oral physostigmine and lecithin on memory and attention in closed head injured patients. Cent. Nerv. Syst. Trauma. 3:1986;333-342
35. Taverni J.P., Seliger G., Lichtman S.W. Donepezil medicated memory improvement in traumatic brain injury post acute rehabilitation. Brain Inj. 12(1):1998;77-80
36. Whelan F.J., Walker M.S., Schultz S.K. Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury. Ann. Clin. Psychiatry. 12(3):2000;131-135
37. Masanic C.A., Bayley M.T., vanReekum R., Simard M. Open-label study of Donepezil in traumatic brain injury. Arch. Phys. Med. Rehabil. 82:2001;896-901
38. Iga J.I., Araki M., Ishimoto Y., Ohmori T. A case of Korsakoff's syndrome improved by high doses of donepezil. Alcohol Alcohol. 36(6):2001;553-555
39. Angunawela I.I., Barker A. Anticholinesterase drugs for alcoholic Korsakoff syndrome. Int. J. Geriatr. Psychiatry. 16(3):2001;338-339
40. Sahin H.A., Gurvit I.H., Bilgic B., Hanagasi H.A., Emre M. Therapeutic effects of an acetylcholinesterase inhibitor (donepezil) on memory in Wernicke-Korsakoff's disease. Clin. Neuropharmacol. 25(1):2002;16-20
41. Jost U., Schmid A., Ruppert M. Physostigmine reversal of central anticholinergic syndrome induced by midazolam/fentanyl, benzoctamine/ buprenorphine and etomidate/carticaine or by atropine/promethazine/pethidine for premedication? Anaesthesist. 31(1):1982;21-24
42. Slatkin N.E., Rhiner M., Maluso Bolton T. Donepezil in the treatment of opioid-induced sedation: report of six cases. J. Pain Symptom Manage. 21(5):2001;425-438
43. Fischer P. Successful treatment on nonanticholinergic delirium with a cholinesterase inhibitor. J. Clin. Psychopharmacol. 21(1):2001;118
44. Gustafson Y., Lundstrom M., Bucht G., Edlund A. Delirium in old age can be prevented and treated. Tidsskr. Nor. Laegeforen. 122(8):2002;810-814
45. Nicolodi M., Galeotti N., Ghelardini C., Bartolini A., Sicuteri F. Central cholinergic challenging of migraine by testing second-generation anticholinesterase drugs. Headache. 42(7):2002;596-602
46. Bullock R., Connolly A. Switching cholinesterase inhibitor therapy in Alzheimer's disease-donepezil to rivastigmine, is it worth it? Int. J. Geriat. Psychiatry. 17:2002;288-289
47. Emre M. Switching cholinesterase inhibitors in patients with Alzheimer's disease. Int. J. Clin. Pract. 127:2002;64-72
48. Auriacombe S., Pere J.J., Loria-Kanza Y., Vellas B. Efficacy and safety of rivagstigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin. 18:2002;129-138
49. Morris J.C. Therapeutic continuity in Alheimer's disease: switching patients to galantamine. Panel discussion: recommendations for prescribers. Clin Ther. 23:2001;A31-A39
50. Mielke R, Winkel M, Goebel C, Berger F. Switching from memantine to donepezil: effects on cognition and quality of life. in: Proceedings of the 18th International Conference of Alzheimer's Disease International (ADI), Barcelona, Spain, 23-26 October 2002.
51. Hartmann S., Mobius H.J. Tolerability of memantine in combination with cholinesterase inhibitors in Alzheimer's disease and vascular dementia. Neurobiol. Aging. 23:2002;S84
52. Wengel S.P., Roccaforte W.H., Burke W.J. Donepezil improves symptoms of delirium in dementia: implications for future research. J. Geriatr. Psychiatry Neurol. 11(3):1998;159-161